Heidelberg Pharm
Price
Price
Frequently asked questions
What is Heidelberg Pharm's market capitalization?
What is the Earnings Per Share (EPS) for Heidelberg Pharm?
What are the analyst ratings and target price for Heidelberg Pharm's stock?
What is Heidelberg Pharm's revenue over the trailing twelve months?
What is the EBITDA for Heidelberg Pharm?
What is the free cash flow of Heidelberg Pharm?
What is the 5-year beta of Heidelberg Pharm's stock?
How many employees does Heidelberg Pharm have, and what sector and industry does it belong to?
What is the free float of Heidelberg Pharm's shares?
Financials
Market Cap
$105.16M5Y beta
-0.83EPS (TTM)
-$0.427Free Float
9.03MRevenue (TTM)
$8.81MEBITDA (TTM)
-$20.26MFree Cashflow (TTM)
-$31.48MPricing
Analyst Ratings
The price target is $11.75 and the stock is covered by 2 analysts.
Buy
2
Hold
0
Sell
0
Information
Heidelberg Pharma AG, formerly Wilex AG, is a Germany-based Company, which is engaged in the biopharmaceuticals sector. The Company focuses on the research and development of therapy treatments for oncology area. It aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. It also offers preclinical contract research services.
98
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker